Carregant...
Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan
Sodium-glucose cotransporter 2 (SGLT2) inhibition induces glucosuria and decreases blood glucose levels in diabetic patients and lowers hypoglycemic risk. SGLT1 is expressed in the kidney and intestine; SGLT1 inhibition causes abdominal symptoms such as diarrhea and reduces incretin secretion. There...
Guardat en:
| Publicat a: | World J Diabetes |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Baishideng Publishing Group Inc
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4317305/ https://ncbi.nlm.nih.gov/pubmed/25685284 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4239/wjd.v6.i1.136 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|